Annual CAPEX
$42.26 M
+$13.70 M+47.98%
31 December 2023
Summary:
Travere Therapeutics annual capital expenditures is currently $42.26 million, with the most recent change of +$13.70 million (+47.98%) on 31 December 2023. During the last 3 years, it has fallen by -$77.59 million (-64.74%). TVTX annual CAPEX is now -64.74% below its all-time high of $119.84 million, reached on 31 December 2020.TVTX CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CAPEX
$8.19 M
-$68.80 M-89.36%
30 September 2024
Summary:
Travere Therapeutics quarterly capital expenditures is currently $8.19 million, with the most recent change of -$68.80 million (-89.36%) on 30 September 2024. Over the past year, it has increased by +$3.27 million (+66.30%). TVTX quarterly CAPEX is now -92.11% below its all-time high of $103.88 million, reached on 31 December 2020.TVTX Quarterly CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CAPEX
$97.18 M
+$3.27 M+3.48%
30 September 2024
Summary:
Travere Therapeutics TTM capital expenditures is currently $97.18 million, with the most recent change of +$3.27 million (+3.48%) on 30 September 2024. Over the past year, it has increased by +$56.26 million (+137.46%). TVTX TTM CAPEX is now -21.94% below its all-time high of $124.50 million, reached on 31 March 2021.TVTX TTM CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TVTX CAPEX Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +48.0% | +66.3% | +137.5% |
| 3 y3 years | -64.7% | +52.4% | -20.9% |
| 5 y5 years | +114.5% | +94.3% | +529.0% |
TVTX CAPEX High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -64.7% | +75.0% | -89.4% | +113.6% | -20.9% | +382.3% |
| 5 y | 5 years | -64.7% | +171.5% | -92.1% | +113.6% | -21.9% | +529.0% |
| alltime | all time | -64.7% | +966.1% | -92.1% | >+9999.0% | -21.9% | >+9999.0% |
Travere Therapeutics CAPEX History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $8.19 M(-89.4%) | $97.18 M(+3.5%) |
| June 2024 | - | $76.99 M(+1090.7%) | $93.92 M(+352.4%) |
| Mar 2024 | - | $6.47 M(+16.9%) | $20.76 M(-50.9%) |
| Dec 2023 | $42.26 M(+48.0%) | $5.53 M(+12.3%) | $42.26 M(+3.3%) |
| Sept 2023 | - | $4.93 M(+28.4%) | $40.93 M(-6.5%) |
| June 2023 | - | $3.84 M(-86.3%) | $43.78 M(-14.6%) |
| Mar 2023 | - | $27.97 M(+566.4%) | $51.26 M(+79.5%) |
| Dec 2022 | $28.56 M(+18.2%) | $4.20 M(-46.1%) | $28.56 M(-3.4%) |
| Sept 2022 | - | $7.78 M(-31.2%) | $29.56 M(+8.9%) |
| June 2022 | - | $11.31 M(+114.8%) | $27.15 M(+34.8%) |
| Mar 2022 | - | $5.27 M(+1.3%) | $20.15 M(-16.6%) |
| Dec 2021 | $24.15 M(-79.8%) | $5.20 M(-3.2%) | $24.15 M(-80.3%) |
| Sept 2021 | - | $5.37 M(+24.8%) | $122.83 M(-1.2%) |
| June 2021 | - | $4.31 M(-53.5%) | $124.37 M(-0.1%) |
| Mar 2021 | - | $9.27 M(-91.1%) | $124.50 M(+3.9%) |
| Dec 2020 | $119.84 M(+670.0%) | $103.88 M(+1402.2%) | $119.84 M(+500.9%) |
| Sept 2020 | - | $6.92 M(+55.9%) | $19.95 M(+15.6%) |
| June 2020 | - | $4.44 M(-3.9%) | $17.25 M(+6.5%) |
| Mar 2020 | - | $4.61 M(+15.9%) | $16.20 M(+4.1%) |
| Dec 2019 | $15.56 M | $3.98 M(-5.6%) | $15.56 M(+0.7%) |
| Sept 2019 | - | $4.22 M(+24.5%) | $15.45 M(+2.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | $3.39 M(-14.9%) | $15.08 M(-2.2%) |
| Mar 2019 | - | $3.98 M(+2.9%) | $15.43 M(-21.7%) |
| Dec 2018 | $19.70 M(+40.6%) | $3.87 M(+0.5%) | $19.70 M(+4.9%) |
| Sept 2018 | - | $3.85 M(+3.0%) | $18.77 M(+0.6%) |
| June 2018 | - | $3.73 M(-54.8%) | $18.66 M(+4.0%) |
| Mar 2018 | - | $8.26 M(+180.8%) | $17.95 M(+28.1%) |
| Dec 2017 | $14.01 M(+17.5%) | $2.94 M(-21.3%) | $14.01 M(-8.4%) |
| Sept 2017 | - | $3.73 M(+23.7%) | $15.30 M(+6.6%) |
| June 2017 | - | $3.02 M(-30.0%) | $14.35 M(+5.2%) |
| Mar 2017 | - | $4.32 M(+2.0%) | $13.64 M(+14.4%) |
| Dec 2016 | $11.92 M(+69.6%) | $4.23 M(+51.8%) | $11.92 M(+26.6%) |
| Sept 2016 | - | $2.79 M(+20.9%) | $9.42 M(+0.1%) |
| June 2016 | - | $2.31 M(-11.3%) | $9.41 M(+8.7%) |
| Mar 2016 | - | $2.60 M(+50.8%) | $8.66 M(+23.1%) |
| Dec 2015 | $7.03 M(+77.3%) | $1.72 M(-38.0%) | $7.03 M(+30.5%) |
| Sept 2015 | - | $2.78 M(+79.0%) | $5.39 M(+94.8%) |
| June 2015 | - | $1.55 M(+59.6%) | $2.77 M(-41.3%) |
| Mar 2015 | - | $973.00 K(+1101.2%) | $4.71 M(+18.8%) |
| Dec 2014 | $3.96 M | $81.00 K(-48.7%) | $3.96 M(+2.1%) |
| Sept 2014 | - | $158.00 K(-95.5%) | $3.88 M(+4.2%) |
| June 2014 | - | $3.50 M(+1437.4%) | $3.73 M(+1537.4%) |
| Mar 2014 | - | $227.50 K | $227.50 K |
FAQ
- What is Travere Therapeutics annual capital expenditures?
- What is the all time high annual CAPEX for Travere Therapeutics?
- What is Travere Therapeutics annual CAPEX year-on-year change?
- What is Travere Therapeutics quarterly capital expenditures?
- What is the all time high quarterly CAPEX for Travere Therapeutics?
- What is Travere Therapeutics quarterly CAPEX year-on-year change?
- What is Travere Therapeutics TTM capital expenditures?
- What is the all time high TTM CAPEX for Travere Therapeutics?
- What is Travere Therapeutics TTM CAPEX year-on-year change?
What is Travere Therapeutics annual capital expenditures?
The current annual CAPEX of TVTX is $42.26 M
What is the all time high annual CAPEX for Travere Therapeutics?
Travere Therapeutics all-time high annual capital expenditures is $119.84 M
What is Travere Therapeutics annual CAPEX year-on-year change?
Over the past year, TVTX annual capital expenditures has changed by +$13.70 M (+47.98%)
What is Travere Therapeutics quarterly capital expenditures?
The current quarterly CAPEX of TVTX is $8.19 M
What is the all time high quarterly CAPEX for Travere Therapeutics?
Travere Therapeutics all-time high quarterly capital expenditures is $103.88 M
What is Travere Therapeutics quarterly CAPEX year-on-year change?
Over the past year, TVTX quarterly capital expenditures has changed by +$3.27 M (+66.30%)
What is Travere Therapeutics TTM capital expenditures?
The current TTM CAPEX of TVTX is $97.18 M
What is the all time high TTM CAPEX for Travere Therapeutics?
Travere Therapeutics all-time high TTM capital expenditures is $124.50 M
What is Travere Therapeutics TTM CAPEX year-on-year change?
Over the past year, TVTX TTM capital expenditures has changed by +$56.26 M (+137.46%)